Table 2 BYG Carba v2.0 results for the 1181 clinical isolates analyzed in this study.
Retrospective collection (n = 511) | Prospective collection (n = 670) | |||
|---|---|---|---|---|
Reference method | Detected by BYG Carba (% of correct results) | Reference method | Detected by BYG Carba (% of correct results) | |
Total CPE | 348 | 330 (94.8) | 356 | 348 (97.8) |
OXA-48-like | 127 | 122 (96.1) | 232 | 227 (97.8) |
KPC | 71 | 71 (100) | 43 | 43 (100) |
NDM | 60 | 56 (93.3) | 47 | 46 (97.9) |
VIM | 52 | 51 (98.1) | 26 | 24 (92.3) |
IMP | 15 | 13 (86.7) | 2 | 2 (100) |
OXA-48-like + NDM | 8 | 8 (100) | 6 | 6 (100) |
IMI | 6 | 4 (66.7) | 0 | NA |
SME | 2 | 2 (100) | 0 | NA |
NMC-A | 1 | 1 (100) | 0 | NA |
GES-5 | 4 | 0 (0) | 0 | NA |
FRI-1 | 1 | 1 (100) | 0 | NA |
GIM-1 | 1 | 1 (100) | 0 | NA |
Total of Non-CPE | 163* | 0 (100) | 314 | 1 (99.7) |
